Protocol No. | UW23106 GO44145 |
||
---|---|---|---|
Principal Investigator | Chang, Julie | ||
Phase | III | ||
Age Group | Adult | ||
ClinicalTrials.Gov | NCT06047080 (Click to jump to clinicaltrials.gov) | ||
Management Group(s) | Lymphoma; UWCCC 1 South Park | ||
Title
Description
Objective
Treatment The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Key Eligibility
Inclusion Criteria:
Previously untreated participants with CD20-positive LBCL Ability to provide tumor tissue International prognostic index (IPI) score 2-5 Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2 At least one bi-dimensionally measurable lesion, defined as > 1.5 cm in its longest dimension as measured by CT or MRI Left ventricular ejection fraction (LVEF) >/=50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO) Adequate hematologic function Negative HIV test at screening with exceptions as defined by the protocol Negative SARS-CoV-2 antigen or PCR test
Applicable Disease Sites
Participating Institutions
|